suven pharmaceuticals - q2 fy21 earnings presentation

24
SUVEN PHARMA Earnings Presentation Q2 & H1FY21

Upload: others

Post on 05-Jan-2022

6 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

SUVEN PHARMAEarnings PresentationQ2 & H1FY21

Page 2: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Risk Statement

Except for historical information, all of the statements, expectations and assumptions, includingexpectations and assumptions, contained in this presentation may be forward-looking statements thatinvolve a number of risks and uncertainties. Although Suven attempts to be accurate in making theseforward-looking statements, it is possible that future circumstances might differ from the assumptionson which such statements are based. Other important factors which could cause these statements todiffer materially including outsourcing trends, economic conditions, dependence on collaborativepartnership programs, retention of key personnel, technological advances and continued success ingrowth of sales that may make our products/services offerings less competitive; Suven may notundertake to update any forward-looking statements that may be made from time to time.

2

Page 3: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Table of Contents

Operation & Financial

Performance Q2FY21

Company Background

144

3

Page 4: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Operation & Financial Performance Q2 FY21

4

Page 5: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Businesswise data

5

206.78

144.17

298.55

269.05

Q2FY20 Q2FY21 H1FY20 H1FY21

CDMO Pharma

Note: Figures in Rs. Crore

54.32

68.22

154.85161.73

Q2FY20 Q2FY21 H1FY20 H1FY21

CDMO Spec Chem

13.21

25

19.9

44.84

Q2FY20 Q2FY21 H1FY20 H1FY21

Formulations & Other

Services

Page 6: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Financial Snapshot

Growth inRevenue

Growth inEBITDA

Growth inPAT

6

Q2FY21 H1FY21

-24.50%-14.59% -20.35%

-8.12%0.73% -10.44%

Page 7: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Key Ratios Q2FY21 Q2FY20

EBIT toIncome

EBITDA to Income

PAT to Income

47.03%

41.58%

45.05%

38.42%

33.41%

31.16%

7

Page 8: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Key Ratios H1FY21 H1FY20

EBIT toIncome

EBITDA to Income

PAT to Income

49.32%

44.98%

47.01%

41.96%

38.67%

34.38%

8

Page 9: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Financials Q2FY21

2,784

2,440 2,377

Q2FY20 Q1FY21 Q2FY21

RUPE

ES M

N

Revenue1,309

1,178

989

Q2FY20 Q1FY21 Q2FY21

RUPE

ES M

N

EBIDTA

3.7 3.6

2.9

Q2FY20 Q1FY21 Q2FY21

RUPE

ES

EPS930 915

741

Q2FY20 Q1FY21 Q2FY21RUPE

ES M

N

PAT

9

Page 10: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Financials H1FY21

4,782 4,817

H1FY20 H1FY21

RUPE

ES M

N

Revenue2,358

2,167

H1FY20 H1FY21

RUPE

ES M

N

EBIDTA

7.3

6.5

H1FY20 H1FY21

RUPE

ES

EPS

1,849

1,656

H1FY20 H1FY21RUPE

ES M

N

PAT

10

Page 11: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Financials Q2FY21

47% 48%42%

Q2FY20 Q1FY21 Q2FY21

EBITDA Margin (%)

33%38%

31%

Q2FY20 Q1FY21 Q2FY21

PAT Margin (%)

11

Page 12: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Financials H1FY21

49%45%

H1FY20 H1FY21

EBITDA Margin (%)

39%34%

H1FY20 H1FY21

PAT Margin (%)

12

Page 13: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Financial Table – Q2 & H1FY21

30-Sep-20 30-Jun-20 30-Sep-19 30-Sep-20 30-Sep-19

Revenue 2,377.45 2,439.72 2,783.73 4,817.16 4,782.09EBITDA 988.50 1,178.47 1,309.31 2,166.97 2,358.44EBITDA Margin 41.58% 48.30% 47.03% 44.98% 49.32%EBIT 913.50 1,107.83 1,253.96 2,021.33 2,248.12EBIT Margin 38.42% 45.41% 45.05% 41.96% 47.01%Finance costs 32.63 32.06 39.91 64.69 74.33Depreciation 75.00 70.63 55.35 145.64 110.32Taxes 227.57 263.47 314.89 491.04 525.38Taxes to PBT 25.83% 24.49% 25.94% 25.10% 24.17%PAT (Standalone) 653.30 812.30 899.16 1,465.60 1,648.41PAT Margin (Standalone) 27.48% 33.29% 32.30% 30.42% 34.47%Unrealised Share of Profit of Associate Company 87.53 103.18 35.22 190.70 208.88PAT (Consolidated) 740.79 915.22 930.05 1,656.01 1,849.09PAT Margin (Consolidated) 31.16% 37.51% 33.41% 34.38% 38.67%EPS (Standalore) Per share 2.57 3.19 3.53 5.76 6.48EPS (Consolidated) 2.91 3.60 3.65 6.51 7.26Paid up share capital (Re.1/sh) 254.56 127.28 127.28 254.56 127.28

All figures are in INR Million, other than ratios and EPS13

Quarter ended Period ended

Page 14: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Company Background

14

Page 15: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Business Model

15

Contract Development

And Manufacturing

Operations (CDMO)

Process Research

Custom Synthesis

Formulation Development Analytical &

Services

Clinical Supplies Mfg& Packaging

Page 16: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Brief Profile

16

BUSINESS OVERVIEW

o Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing.

KEY STRENGTHS

o Preferred global outsourcing partner with capabilities across the entire CDMO value chain.

o Strong chemistry skills.

FINANCIAL OVERVIEW

o Revenues, EBITDA and Consolidated PAT of Rs 4817 Mn, Rs 2166 Mn and Rs 147 Mn in FH-FY21.

o Strong balance sheet with D:E ratio of 0.12 as on Mar-20.

Page 17: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Suven is an integrated Contract Development and Manufacturing Operations company

Suven Pharmaceuticals provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations.

Since our founding in 1989, Suven has established its core competency in cyanation and heterocyclic chemistry, including pyrimidines, quinolones, thiazoles, and imidazoles, in addition to demonstrating our proficiency in Carbohydrate and Chiral chemistry including tetrahydrofurans, amino acids and sulfoxides from gram to multi-ton scale.

Suven effectively uses its expanding infrastructure and ability to collaborate, from route scouting and development through commercial manufacture, to provide a consistent and reliable partner throughout a product's life cycle.

Suven is dedicated to going beyond commitment and delivering R&D and Manufacturing solutions, with flexibility, quality, speed, and cost effectiveness.

17

Page 18: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Our Focus

A full-fledged bio-pharmaceutical solutions provider for global pharmaceutical companies

18

NCE based CDMO

18

Page 19: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Financial Approach

19

Shareholder value creation

focus

Consistently dividend paying

Prudent utilisation of cash flows

Low debt

Page 20: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Business Drivers

20

State of the art facilities located across India and

US

Present across the entire CDMO value

chain –intermediates &

APIs

Leveraging on research capabilities to delivering NCE

research

An integrated research service provider with

unmatched capabilities

Page 21: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Business Drivers

21

Repeat business owing to long

standing relationships with MNC companies

Long term commercial supply opportunity with

the launch of product by global

sponsors

Working with innovator companies in developed markets

having stringent regulations –

reflection of our research skills

Over 90% of revenues from

regulated markets

Page 22: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Multi Location Facilities

Suryapet, Telangana, India

Intermediate Mfg. Facility

Banjara Hills, Hyderabad, India

Corporate Office

Pashamylaram, Telangana, India

API & Formulation Facility

Jeedimetla, Telangana, India

R&D–Pilot Plant

USA, New Jersey

Business Office

o Business Developmento Project Managemento Intellectual Property

Management

o Process Researcho Discovery R&D, Analytical R&Do Killo lab, 30L CM Reactors (32)o 50L – 4000 L GL/SS

o 300 CM reactors (93)o 500L to 10 KL GL/SSo GMP Intermediates

o 120 kL reaction volumeo 50L – 6000 L GL/SS (45)o API Manufacturing o Formulation R&D

o 307 KL reactor volumeo 3KL to 12KL Reactorso GL/SS (45No’s)o API’s/Advanced

Intermediate’s/CMO

Vizag, Andhra

Pradesh, India

22

Page 23: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Contact

Suven Pharmaceuticals Ltd

Email: [email protected]

For more info: www.suvenpharm.com

For queries and requests, please contact:

Gavin Desa / Rishab Barar

CDR - India

Tel: +91 22 6645 1237 / 1235

Email: [email protected]

[email protected]

Suven Pharmaceuticals Ltd# 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA.

+91-40-2354-9414 /1142 /3311

23

Page 24: Suven Pharmaceuticals - Q2 FY21 Earnings Presentation

Thank You